We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
CXR Biosciences  Licenses the Rosetta Resolver Gene Expression Data Analysis System from Rosetta Biosoftware
News

CXR Biosciences Licenses the Rosetta Resolver Gene Expression Data Analysis System from Rosetta Biosoftware

CXR Biosciences  Licenses the Rosetta Resolver Gene Expression Data Analysis System from Rosetta Biosoftware
News

CXR Biosciences Licenses the Rosetta Resolver Gene Expression Data Analysis System from Rosetta Biosoftware

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CXR Biosciences Licenses the Rosetta Resolver Gene Expression Data Analysis System from Rosetta Biosoftware"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Rosetta Biosoftware has announced that CXR Biosciences Ltd., licensed the Rosetta Resolver® system to investigate mechanisms of drug toxicity.

CXR Biosciences plans to use the statistical analysis tools in the Resolver system to generate data to support its toxicological research using transcriptional profiling.

“We appreciate Rosetta Biosoftware's strong reputation for developing high-quality data management and statistical software for microarray analysis," said Tom Shepherd, Ph.D., Chief Executive Officer of CXR Biosciences.

“The Resolver system will provide us with a solid platform for determining the toxicological profiles of early-stage compounds, helping us to achieve one of CXR's strategic aims, which is to revolutionize the human risk assessment of drugs and chemicals.”

“At Rosetta Biosoftware, we developed the Resolver system to be a flexible and scalable framework to grow with a researcher's throughput needs,” said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware.

Advertisement